Recently, a strategic cooperation and exclusive licensing agreement for Ticagrelor Tablets and Rosuvastatin Calcium Tablets across multiple European countries was signed between Kexing Biopharm and Changzhou Pharmaceutical Factory Co., Ltd. (hereinafter referred to as "Changzhou Pharmaceutical Factory"), a subsidiary of Shanghai Pharmaceutical Group.

Kexing Biopharm’s overseas commercial product Paclitaxel for Injection (Albumin Bound) (Apexelsin®), has received marketing authorization in Macao (China) and Malaysia.

Kexing Biopharm's Overseas Commercial Product——Liraglutide, the product exported in cooperation with Tonghua Dongbao Pharmaceutical, officially obtained the Good Manufacturing Practice (GMP) certificate issued by the Brazilian National Health Surveillance Agency (ANVISA).

Kexing Biopharm's innovative drug "GB19 Injection" for the treatment of systemic lupus erythematosus (SLE) received approval from National NMPA to conduct clinical trials in China. In preclinical studies, GB19 demonstrated high potency, favorable bioavailability, sustained target inhibition for over 90 days, low immunogenicity, and excellent safety profile.

Kexing Biopharm successfully secured the "Most Valuable Brand Award" for its profound brand heritage and industry influence.

Recently, GB10 Injection—a high-concentration ophthalmic-specific protein formulation of an anti-VEGF/Ang-2 dual-target antibody independently developed by the company and holding global intellectual property rights—has officially received the Drug Clinical Trial Approval Notification from the National Medical Products Administration (Acceptance No.: CXSL2500841), granting permission to initiate clinical trials for the treatment of neovascular age-related macular degeneration (nAMD).

Recently, the Reminton (Infliximab for Injection) licensed in by the company from Mabpharm Limited has been approved for marketing by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia.

Recently, another licensed-in product from Kexing Biopharm Co., Ltd. (688136.SH) - Liraglutide Injection developed by Tonghua Dongbao Pharmaceutical - has been approved for marketing by Peru's National Drug and Medical Device Agency (DIGEMID).